Amplify Cybersecurity ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Amplify Cybersecurity ETF trades at $119.17, while Regeneron Pharmaceuticals Inc trades at $808.88 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals.
| HACK | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $119.19 | $812.27 |
52-Week Low | $70.69 | $545.94 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.
The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →